T
Takashi Itoh
Researcher at Takeda Pharmaceutical Company
Publications - 18
Citations - 1644
Takashi Itoh is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Recombinant DNA & Peptide. The author has an hindex of 8, co-authored 18 publications receiving 1458 citations.
Papers
More filters
Journal ArticleDOI
A G Protein-coupled Receptor Responsive to Bile Acids
Yuji Kawamata,Ryo Fujii,Masaki Hosoya,Masataka Harada,Hiromi Yoshida,Masanori Miwa,Shoji Fukusumi,Yugo Habata,Takashi Itoh,Yasushi Shintani,Shuji Hinuma,Yukio Fujisawa,Masahiko Fujino +12 more
TL;DR: It is found that a novel G protein-coupled receptor, TGR5, is responsive to bile acids as a cell-surface receptor, and was abundantly expressed in monocytes/macrophages in human and rabbit.
Journal ArticleDOI
Stimulation effect of galanin-like peptide (GALP) on luteinizing hormone-releasing hormone-mediated luteinizing hormone (LH) secretion in male rats.
Hirokazu Matsumoto,Jiro Noguchi,Yoshihiro Takatsu,Yasuko Horikoshi,Satoshi Kumano,Tetsuya Ohtaki,Chieko Kitada,Takashi Itoh,Haruo Onda,Osamu Nishimura,Masahiko Fujino +10 more
TL;DR: It is found that intracerebroventricular administration of GALP increased the plasma LH level but did not change the levels of other hormones, and accumulation of c-Fos protein was dramatically increased in the nuclei of LHRH-positive cells in the MPA by icv GALp administration.
Journal ArticleDOI
Galanin-like peptide stimulates food intake in the rat.
Yoshio Matsumoto,Takuya Watanabe,Yuka Adachi,Takashi Itoh,Tetsuya Ohtaki,Haruo Onda,Tsutomu Kurokawa,Osamu Nishimura,Masahiko Fujino +8 more
TL;DR: Results suggest that GALP is a novel orexigenic and anxiogenic peptide, as a ligand for galanin receptor subtype GalR2, and the effect of the intracerebroventricular administration of GALp induced food intakes.
Journal ArticleDOI
Renaturation of recombinant human neurotrophin-3 from inclusion bodies using a suppressor agent of aggregation.
TL;DR: In this paper, the authors applied the refolding process using the aggregation suppressor Larginine in the renaturation of neurotrophin-3, and obtained biologically active recombinant human neurotrophic protein from the inclusion bodies.
Journal ArticleDOI
Topical application of neurotrophin-3 attenuates ischemic brain injury after transient middle cerebral artery occlusion in rats.
Wen Ri Zhang,H. Kitagawa,Takeshi Hayashi,Chihoko Sasaki,Kyoji Sakai,Hitoshi Warita,Yoshihiko Shiro,H. Suenaga,Hiroaki Ohmae,Shinji Tsuji,Takashi Itoh,Osamu Nishimura,H. Nagasaki,Koji Abe +13 more
TL;DR: Terminal deoxynucleotidyl transferase-mediated dUTP-biotin in situ nick labeling (TUNEL) staining and immunohistochemical study for caspase-3 and heat shock protein 72 (HSP72) showed that NT-3 treatment decreased the number of cells with DNA fragmentation and caspases and HSP72 expressions.